The role of tigecycline in the treatment of infections in light of the new black box warning

References

• Kasbekar N. Tigecycline: a new glycycline antimicrobial agent. Am J Health Syst Pharm 2006;63(13):1235-43
   PubMed Web of Science ®Google Scholar
• Tygacil (Tigecycline), package insert. Pfizer,Inc., Philadelphia, PA, USA; 2005
   Google Scholar
• Livermore DM. Tigecycline: what is it, and where should it be used? J Antimicrob Chemother 2005;56(4):611-14
   PubMed Web of Science ®Google Scholar
• US FDA. FDA drug safety communication: increased risk of death with Tygacil (Tigecycline) compared to other antibiotics used to treat similar infections. 2010 [ Last accessed December 2013
   Google Scholar
• US FDA. FDA drug safety communication: FDA warns of increased risk of death with IV antibacterial Tygacil (Tigecycline) and approves new Boxed Warning. 2013 [ Last accessed December 2013
   Google Scholar
• Ellis-Grosse EJ, Babinchak T, Dartois N, et al. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of two double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 2005;41(Suppl 5):S341-53
   PubMedGoogle Scholar
• Fomin P, Beuran M, Gradauskas A, et al. Tigecycline is efficacious in the treatment of complicated intra-abdominal infections. Int J Surg 2005;3(1):35-47
   PubMedGoogle Scholar
• Bergallo C, Jasovich A, Teglia O, et al. Safety and efficacy intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin. Diagn Microbiol Infect Dis 2009;63(1):52-61
   PubMed Web of Science ®Google Scholar
• Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010;68(2):140-51
   PubMed Web of Science ®Google Scholar
• Ramirez J, Dartois N, Gandjini H, et al. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013;57(4):1756-62
   PubMed Web of Science ®Google Scholar
• Cai Y, Wang R, Liang B, et al. Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease. Antimicrob Agents Chemother 2011;55(3):1162-72
   PubMed Web of Science ®Google Scholar
• Yahav D, Lador A, Paul M, Leibovici L. Efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66:1963-71
   PubMed Web of Science ®Google Scholar
• Tasina E, Haidich AB, Kokkali S, et al. Efficacy and safety of tigecycline for the treatment of infectious diseases: a meta-analysis. Lancet Infect Dis 2011;11:834-44
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Interpretation of tests of heterogeneity and bias in meta-analysis. J Eval Clin Pract 2008;14(5):951-7
   PubMed Web of Science ®Google Scholar
• Prasad P, Sun J, Danner RL, et al. Excess deaths associated with tigecycline after approval based on non-inferiority trials. Clin Infect Dis 2012;54:1699-709
   PubMed Web of Science ®Google Scholar
• Powers J. Asking the right questions: morbidity, mortality, and measuring what’s important in unbiased evaluations of antimicrobials. Clin Infect Dis 2012;54(12):1710-13
   PubMed Web of Science ®Google Scholar
• Curcio D, Verde PE. Comment on: efficacy and safety of tigecycline: a systematic review and meta-analysis. J Antimicrob Chemother 2011;66(12):2893-5
   PubMedGoogle Scholar
• Verde PE, Curcio D. Imbalanced mortality evidence for tigecycline: 2011, the year of the meta-analysis. Clin Infect Dis 2012;55(3):471-2
   PubMed Web of Science ®Google Scholar
• Poulakou G, Kontopidou F, Paramythiotou E, et al. Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens. J Infect 2009;58:273-84
   PubMed Web of Science ®Google Scholar
• Rodríguez-Avial C, Rodríguez-Avial I, Merino P, Picazo JJ. Klebsiellapneumoniae: development of a mixed population of carbapenem and tigecycline resistance during antimicrobial therapy in a kidney transplant patient. Clin Microbiol Infect 2012;18:61-6
   PubMed Web of Science ®Google Scholar
• Hornsey M, Loman N, Wareham DW, et al. Whole-genome comparison of two Acinetobacter baumannii isolates from a single patient, where resistance developed during tigecycline therapy. J Antimicrob Chemother 2011;66:1499-503
   PubMed Web of Science ®Google Scholar
• Chen LY, Chen TC, Chen YH, et al. Microbial isolation and emer- gence of antimicrobial resistance associated with tigecycline usage. J Microbiol Immunol Infect 2011;44:352-7
   PubMedGoogle Scholar
• Gallagher JC, Rouse HM. Tigecycline for the treatment of Acinetobacter infections: a case series. Ann Pharmacother 2008;42:1188-94
   PubMed Web of Science ®Google Scholar
• Sun Y, Cai Y, Liu X, et al. The emergence of clinical resistance to tigecycline. Int J Antimicrob Agents 2013;41:110-16
   PubMed Web of Science ®Google Scholar
• Entenza JM, Moreillon P. Tigecycline in combination with other antimicrobials: a review of in vitro, animal and case report studies. Int J Antimicrob Agents 2009;34(1):8. e1–8.e9
   PubMed Web of Science ®Google Scholar
• Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumonia carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. Antimicrob Chemother 2010;12:12
   Google Scholar
• Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012;56(4):2108-13
   PubMed Web of Science ®Google Scholar
• Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011;17:1798-803
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by KPC-producing Klebsiella pneumoniae: importance of combination therapy. Clin Infect Dis 2012;55(7):943-50
   PubMed Web of Science ®Google Scholar